Former FDA top oncology regulator Rick Pazdur discusses the agency’s recent political appointees and suggests a chance for fundamental restructuring amid growing Chinese drug industry competition.
Rick Pazdur, the former top oncology regulator at the Food and Drug Administration (FDA), has highlighted significant damage done under recent political appointees as an opportunity for new leadership to fundamentally restructure the agency. Speaking at a STAT event during the annual meeting of the American Society of Clinical Oncology in Chicago, Pazdur emphasized that this period of change offers a chance to rethink how the FDA operates.
Pazdur noted, "We've had a lot of destruction here under leaders appointed by the Trump administration, and it doesn't mean we have to just go back and say, well, let's rebuild it as it was." He suggested that this situation presents an opportunity for new leadership to reimagine the agency’s administrative structure, staffing needs, and overall approach. "This gives us a great opportunity of — how we want to build it, what staff we want to have, how we want the administrative structure to be," he said.
One key area Pazdur highlighted was the loss of valuable experts at the FDA. To address this, he proposed thinking creatively about staffing solutions, such as bringing in academics and industry professionals for one- or two-year terms. "We need to think outside the box on how we can bring in talent that might not traditionally be part of our agency," Pazdur explained.
As China’s drug industry continues to grow more competitive, Pazdur believes this restructuring is crucial for maintaining the FDA's effectiveness. He stressed that the agency must adapt and evolve to meet new challenges while retaining its core mission of ensuring public health through rigorous drug regulation.
